Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study

Published Mar 25, 2026Diabetes, obesity & metabolism

Oral Semaglutide Use and Related Health Results in Thai People with Type 2 Diabetes: Real-World Data from the REALISED Study

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Page updated Mar 27, 2026

Abstract

Mean HbA1c decreased by -0.7% among 195 Thai patients with type 2 diabetes using oral semaglutide.

Oral semaglutide was mainly used as an add-on therapy in 97.4% of patients.
At the end of 26 weeks, 75.9% of participants achieved an HbA1c level below 7%.
Mean body weight decreased by -4.3 kg over the same period.
A composite endpoint combining an HbA1c < 7% and ≥ 3% weight loss was met by 57.7% of patients.
No severe hypoglycaemia incidents were reported during the study.

AI simplified

AIMS: The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real-world clinical settings.

MATERIALS AND METHODS: This retrospective, multi-centre cohort study included 195 patients with T2D initiating oral semaglutide between April 2022 and December 2023. Eligible participants had no prior injectable therapy and completed at least 26 weeks of treatment. The primary endpoint was the change in HbA1c from baseline to the end-of-study (EoS, Week 26); Week 52 outcomes were exploratory. Secondary endpoints included changes in body weight and the proportion achieving HbA1c < 7%. Severe hypoglycaemia was the safety endpoint. A post hoc composite endpoint combined HbA1c < 7% with ≥ 3% weight loss. Analyses used a mixed model for repeated measures and descriptive statistics.

RESULTS: Oral semaglutide was predominantly used as add-on therapy (190/195 [97.4%]). Mean HbA1c decreased by -0.7% (95% CI: -0.9 to -0.5; p < 0.0001), and the mean body weight decreased by -4.3 kg (95% CI: -5.5 to -3.2; p < 0.0001). At the EoS, 75.9% (117/154) achieved an HbA1c < 7%, and 57.7% (71/123) met the composite endpoint. No severe hypoglycaemia occurred. Dose escalation from 3 mg to 14 mg was observed in 53.2% by Week 26 and 70.4% by Week 52.

CONCLUSIONS: The REALISED study provides the first real-world evidence of the use of oral semaglutide in Thai patients with T2D, demonstrating significant improvements in glycaemic control and weight reduction across routine care settings.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief